Caplin Point Laboratories Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Caplin Point Laboratories Limited Pharmaceutical Export Portfolio Dataset — 55 Products, $174.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Caplin Point Laboratories Limited — Pharmaceutical Exporter Profile (2026) | 55 Products, $174.5M Trade | TransData Nexus

Caplin Point Laboratories Limited

Indian Pharmaceutical Exporter · Analgesics & Antipyretics Specialist · $174.5M Total Trade · DGFT Verified

Caplin Point Laboratories Limited is an Indian pharmaceutical exporter with a total trade value of $174.5M across 55 products in 20 therapeutic categories. Based on 4,392 verified export shipments from Indian Customs (DGFT) records, Caplin Point Laboratories Limited is the #1 Indian exporter in 3 products including Clotrimazole, Vitamin, Secnidazole. Top exports include Ibuprofen ($31.4M), Diclofenac ($15.5M), Clotrimazole ($12.0M).

Caplin Point Laboratories Limited — Export Portfolio & Destination Treemap

Caplin Point Laboratories Limited pharmaceutical export portfolio — 55 products across 20 therapeutic categories. Source: Indian Customs (DGFT).

Who is Caplin Point Laboratories Limited? — Company Overview & Market Position

Caplin Point Laboratories Limited, established in 1990, is a prominent Indian pharmaceutical company specializing in the development, production, marketing, and export of generic formulations and branded products. Headquartered in Chennai, Tamil Nadu, the company operates under the Corporate Identification Number (CIN) L24231TN1990PLC019053. Listed on the Bombay Stock Exchange (BSE) under the ticker symbol 524742 and the National Stock Exchange (NSE) as CAPLIPOINT, Caplin Point has demonstrated significant growth and market presence.

The company offers a diverse product portfolio, including tablets, capsules, injections, ophthalmic solutions, liquid orals, softgel capsules, ointments, creams, gels, and more. With over 4,000 product registrations across more than 36 therapeutic areas, Caplin Point has established a strong foothold in various global markets.

As of March 2026, Caplin Point Laboratories Limited employs approximately 3,966 individuals, reflecting its substantial operational scale. The company's official website, www.caplinpoint.net, provides comprehensive information about its products, services, and corporate initiatives.

What Does Caplin Point Laboratories Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ibuprofen

Product Portfolio — Top 30 by Export Value

Caplin Point Laboratories Limited exports 55 pharmaceutical products across 20 therapeutic categories. Market leader (#1 exporter) in 3 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ibuprofen	Analgesics & Antipyretics	$31.4M	627	5.4%	3
2	Diclofenac	Analgesics & Antipyretics	$15.5M	310	4.3%	5
3	Clotrimazole	Antifungals	$12.0M	302	13.0%	1
4	Potassium	Nutritional Supplements	$11.3M	225	1.8%	9
5	Vitamin	Nutritional Supplements	$10.6M	373	7.4%	1
6	Losartan	Cardiovascular	$7.3M	146	2.4%	11
7	Lansoprazole	Gastrointestinal	$6.4M	128	2.2%	6
8	Gentamicin	Antibiotics	$6.0M	136	11.7%	2
9	Amino	Nutritional Supplements	$5.5M	110	1.7%	8
10	Clarithromycin	Antibiotics	$5.5M	110	5.6%	4
11	Irbesartan	Cardiovascular	$5.3M	106	5.0%	3
12	Acetaminophen	Analgesics & Antipyretics	$5.2M	103	2.2%	6
13	Omeprazole	Gastrointestinal	$5.1M	135	0.8%	15
14	Fluconazole	Antifungals	$4.8M	99	5.2%	5
15	Albendazole	Antimalarial & Antiparasitic	$3.9M	130	5.4%	5
16	Heparin	Cardiovascular	$3.7M	74	1.0%	3
17	Cefixime	Advanced Antibiotics	$3.5M	98	2.0%	9
18	Hydrochlorothiazide	Diuretics	$3.5M	69	0.8%	9
19	Azithromycin	Antibiotics	$2.9M	57	1.5%	13
20	Metronidazole	Advanced Antibiotics	$2.2M	132	1.1%	14
21	Secnidazole	Advanced Antibiotics	$2.1M	42	6.9%	1
22	Artesunate	Antimalarial & Antiparasitic	$2.0M	49	1.2%	9
23	Amoxicillin	Antibiotics	$1.9M	38	0.3%	12
24	Allopurinol	Lipid & Metabolism	$1.6M	90	0.3%	8
25	Loratadine	Antihistamines & Allergy	$1.5M	116	0.9%	12
26	Erythromycin	Antibiotics	$1.2M	24	1.5%	11
27	Ketoconazole	Antifungals	$1.1M	69	2.9%	6
28	Nystatin	Antifungals	$976.5K	66	1.9%	10
29	Vancomycin	Antibiotics	$976.4K	23	1.1%	13
30	Syringe	Medical Devices & Diagnostics	$975.0K	35	0.5%	14

Caplin Point Laboratories Limited exports 55 pharmaceutical products across 20 therapeutic categories with a total export value of $174.5M. The company is the #1 Indian exporter in 3 products: Clotrimazole, Vitamin, Secnidazole. The top category is Analgesics & Antipyretics (30.3% of portfolio), followed by Nutritional Supplements (16.4%), reflecting a diversified portfolio where the top 5 products account for only 46.2% of total value.

Showing top 30 of 55 products. Contact us for complete data.

Caplin Point Laboratories Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Caplin Point Laboratories Limited operates multiple manufacturing facilities across India, each designed to cater to specific market needs and regulatory standards. The primary manufacturing plant, located in Suthukeny, Puducherry, is approved by INVIMA (Colombia) and WHO-GMP, focusing on emerging markets in Latin America and Africa. This facility produces a wide range of dosage forms, including sterile liquids, lyophilized injectables, pre-filled syringes, tablets, capsules, liquid orals, soft gelatin capsules, dry powder for oral suspension, suppositories, ovules, and topicals such as creams, lotions, and ointments.

Another significant facility is Caplin Steriles Limited (CP-IV), which specializes in sterile injectables and ophthalmic products. This plant is approved by the US FDA, EU-GMP, INVIMA, and WHO-GMP, underscoring its compliance with stringent international quality standards.

3Key Leadership

Caplin Point Laboratories Limited is led by a team of seasoned professionals committed to driving the company's growth and strategic direction. Mr. C.C. Paarthipan serves as the Chairman, bringing nearly three decades of experience in the pharmaceutical industry. His leadership has been instrumental in expanding the company's global footprint, particularly in Latin America and Africa.

Dr. Sridhar Ganesan, the Managing Director and Whole-Time Director, has over 35 years of global leadership experience in the pharmaceutical sector. His expertise spans profit center management, global marketing, and international collaborations, contributing significantly to Caplin Point's rapid growth and market presence.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Caplin Point Laboratories Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Caplin Point Laboratories Limited has established a robust presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's subsidiary, Caplin Steriles Limited, has received multiple approvals from the US FDA, including for Labetalol Hydrochloride Injection USP in September 2021 and Desmopressin Acetate Injection USP in February 2026. These approvals highlight Caplin Point's commitment to meeting the stringent regulatory requirements of these markets.

In the European Union, Caplin Point's manufacturing facilities are certified under EU-GMP, ensuring compliance with European quality standards. The company's products are also approved by regulatory bodies in other regions, such as ANVISA in Brazil, INVIMA in Colombia, and COFEPRIS in Mexico, facilitating access to various international markets.

2Emerging Markets

Caplin Point Laboratories Limited has strategically penetrated emerging markets in Africa, Latin America, and Southeast Asia. The company's manufacturing facility in Puducherry is approved by INVIMA (Colombia) and WHO-GMP, enabling access to these regions. Additionally, Caplin Point's subsidiary, Caplin Steriles USA Inc., operates as a sales and marketing arm in the U.S. market, focusing on high-quality injectables and ophthalmic products.

Geographic Strategy

Caplin Point Laboratories Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Caplin Point Laboratories Limited's subsidiary, Caplin Steriles Limited, has achieved significant milestones with the US FDA. In September 2021, it received final approval for Labetalol Hydrochloride Injection USP, a generic therapeutic equivalent of TRANDATE Injection. In February 2026, Caplin Steriles Limited secured final approval for Desmopressin Acetate Injection USP, a generic version of DDAVP Injection. These approvals underscore Caplin Point's commitment to meeting the stringent standards of the US FDA.

2WHO & EU GMP

Caplin Point Laboratories Limited's manufacturing facilities are certified under WHO-GMP and EU-GMP, ensuring compliance with international quality standards. The company's facility in Puducherry is approved by WHO-GMP, facilitating access to emerging markets in Africa and Latin America. Additionally, Caplin Steriles Limited's plant is approved by EU-GMP, enabling entry into the European market.

3CDSCO & Indian Regulatory

Caplin Point Laboratories Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Caplin Point Laboratories Limited operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. Its focus on generic formulations and branded products positions it against other Indian pharmaceutical exporters and global generics manufacturers. The company's strategic presence in emerging markets, coupled with its regulatory approvals, provides a competitive edge in these regions.

2Key Differentiators

Caplin Point Laboratories Limited distinguishes itself through its diversified product portfolio, encompassing over 4,000 product registrations across more than 36 therapeutic areas. The company's manufacturing facilities are approved by multiple international regulatory bodies, including the US FDA, EU-GMP, INVIMA, and WHO-GMP, ensuring compliance with global quality standards. Additionally, Caplin Point's strategic focus on emerging markets in Latin America, Africa, and Southeast Asia allows it to address the healthcare needs of underserved populations.

3Strategic Position

Caplin Point Laboratories Limited's current strategic direction emphasizes the development and manufacturing of generic formulations and branded products, with a particular focus on injectables and ophthalmic products. The company's recent approvals from the US FDA for products like Labetalol Hydrochloride Injection USP and Desmopressin Acetate Injection USP reflect its commitment to expanding its presence in regulated markets. Looking ahead, Caplin Point aims to leverage its manufacturing capabilities and regulatory approvals to further penetrate global markets and address the evolving healthcare needs of diverse populations.

Buyer Due Diligence Brief — Evaluating Caplin Point Laboratories Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Caplin Point Laboratories Limited has demonstrated a strong track record in the pharmaceutical industry, with a diverse product portfolio and a global presence. The company's manufacturing facilities are approved by multiple international regulatory bodies, including the US FDA, EU-GMP, INVIMA, and WHO-GMP, indicating a high level of compliance with global quality standards. Caplin Point's strategic focus on emerging markets in Latin America, Africa, and Southeast Asia, coupled with its recent regulatory approvals, underscores its reliability as a supplier capable of meeting

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Caplin Point Laboratories Limited

How many pharmaceutical products does Caplin Point Laboratories Limited export from India?

Caplin Point Laboratories Limited exports 55 pharmaceutical products across 20 therapeutic categories. The top exports are Ibuprofen ($31.4M), Diclofenac ($15.5M), Clotrimazole ($12.0M), Potassium ($11.3M), Vitamin ($10.6M). Total export value is $174.5M.

What is Caplin Point Laboratories Limited's total pharmaceutical export value?

Caplin Point Laboratories Limited's total pharmaceutical export value is $174.5M, based on 4,392 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Caplin Point Laboratories Limited the #1 Indian exporter?

Caplin Point Laboratories Limited is the #1 Indian exporter in 3 products: Clotrimazole (13.0% market share), Vitamin (7.4% market share), Secnidazole (6.9% market share).

What therapeutic categories does Caplin Point Laboratories Limited cover?

Caplin Point Laboratories Limited exports across 20 therapeutic categories. The largest are Analgesics & Antipyretics (30.3%, 4 products), Nutritional Supplements (16.4%, 6 products), Antifungals (11.3%, 6 products).

Get Full Caplin Point Laboratories Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.